Myriad Genetics, Inc. announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2025.
The company provided full year 2026 financial guidance including revenue, adjusted gross margin, and adjusted EBITDA projections.
Actual financial results for 2025 will be released during an earnings call in February 2026.
Fourth Quarter 2025 Revenues
Expected to be between $207 million and $209 million.
Full Year 2025 Revenues
Expected to be between $822 million and $824 million.
2026 Financial Guidance
Revenue guidance of $860 - $880 million, adjusted gross margin of 68% - 69%, and adjusted EBITDA of $37 - $49 million.
- The mid-point of the 2026 revenue guidance range indicates a 6% increase compared to the mid-point of the preliminary 2025 revenue range.
- Adjusted EBITDA is expected to grow by approximately 43% over the 2025 guidance range.
- The financial projections incorporate potential impacts from new product launches and other factors.
These forward-looking statements highlight Myriad Genetics' performance and expectations for the upcoming financial periods, emphasizing growth and strategic positioning in the market.